MX9708854A - Terapia de genes para regulacion de celulas efectoras. - Google Patents
Terapia de genes para regulacion de celulas efectoras.Info
- Publication number
- MX9708854A MX9708854A MX9708854A MX9708854A MX9708854A MX 9708854 A MX9708854 A MX 9708854A MX 9708854 A MX9708854 A MX 9708854A MX 9708854 A MX9708854 A MX 9708854A MX 9708854 A MX9708854 A MX 9708854A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- encoding nucleic
- present
- acid molecules
- gene therapy
- Prior art date
Links
- 239000012636 effector Substances 0.000 title abstract 2
- 230000009134 cell regulation Effects 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 7
- 102000039446 nucleic acids Human genes 0.000 abstract 7
- 108020004707 nucleic acids Proteins 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 3
- 239000002671 adjuvant Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invencion provee una composicion terapéutica basada en ácido nucleico para tratar a un animal enfermo controlando la actividad de células efectoras, incluyendo células T, macrofagos, monocitos y/o células asesinas naturales en el animal. Las composiciones terapéuticas de la presente invencion incluyen moléculas de ácido nucleico que codifican superantígeno, ya sea en presencia o ausencia de una molécula de ácido nucleico que codifica citoquina y/o moléculas de ácido nucleico que codifican quimioquina, dependiendo de la enfermedad que se está tratando. La presente invencion también se refiere a un auxiliar para usarse con vacunas basadas en ácido nucleico. Composiciones auxiliares de la presente invencion incluyen un inmunogeno combinado con moléculas de ácido nucleico que codifican superantígeno, ya sea en presencia o ausencia de una molécula de ácido nucleico que codifica citoquina y/o moléculas de ácido nucleico que codifican quimioquina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/446,918 US5705151A (en) | 1995-05-18 | 1995-05-18 | Gene therapy for T cell regulation |
US08/580,806 US5935568A (en) | 1995-05-18 | 1995-12-29 | Gene therapy for effector cell regulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9708854A true MX9708854A (es) | 1998-08-30 |
Family
ID=27034800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9708854A MX9708854A (es) | 1995-05-18 | 1997-11-17 | Terapia de genes para regulacion de celulas efectoras. |
Country Status (8)
Country | Link |
---|---|
US (1) | US5935568A (es) |
EP (1) | EP0850071A4 (es) |
JP (1) | JPH11508762A (es) |
KR (1) | KR19990014875A (es) |
AU (1) | AU704012B2 (es) |
CA (1) | CA2221305A1 (es) |
MX (1) | MX9708854A (es) |
WO (1) | WO1996036366A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075119A (en) * | 1997-04-07 | 2000-06-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
US6713284B2 (en) | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
KR20010022075A (ko) * | 1997-07-21 | 2001-03-15 | 존 헤덴스트룀 | T세포활성화를유도하는슈퍼항원접합체에의한표적세포의세포용해 |
US7795020B2 (en) | 1998-01-14 | 2010-09-14 | Morphogenesis, Inc. | Tumor cell vaccines |
US7348015B2 (en) | 1998-01-14 | 2008-03-25 | Morphogenesis, Inc. | Antigen modified cancer cell vaccines for cancer therapy |
WO1999036433A2 (en) | 1998-01-14 | 1999-07-22 | Morphogenesis, Inc. | Materials and methods for treating oncological disease |
ATE281844T1 (de) * | 1998-01-16 | 2004-11-15 | Univ Johns Hopkins | Orale verabreichung von nukleinsäure-impstoffen durch partikelkomplexe |
CN100352930C (zh) * | 1998-02-27 | 2007-12-05 | 宾夕法尼亚州立大学托管会 | 疫苗、免疫治疗剂及其应用方法 |
JP4540845B2 (ja) * | 1998-04-20 | 2010-09-08 | トーレイ パインズ インスティテュート フォー モレキュラー スタディーズ | ランゲルハンス細胞遊走を誘導する局所的免疫刺激 |
WO1999053960A2 (en) * | 1998-04-22 | 1999-10-28 | Chiron Corporation | Enhancing immune responses to genetic immunization by using a chemokine |
US6919318B1 (en) | 1998-04-22 | 2005-07-19 | Chiron Corporation | Enhancing immune responses to genetic immunization by using a chemokine |
AU748565B2 (en) * | 1998-06-23 | 2002-06-06 | Board Of Trustees Of The Leland Stanford Junior University | Adjuvant therapy |
US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
DE69940157D1 (en) * | 1998-07-10 | 2009-02-05 | U S Medical Res Inst Of Infect | Anthrax-impfstoff |
MXPA01001631A (es) * | 1998-08-13 | 2002-04-08 | Walter Reed Army Inst Of Res D | Vacunas de superantigenos bacterianos. |
AU6059799A (en) * | 1998-10-07 | 2000-04-26 | Rockefeller University, The | Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
US6562800B1 (en) * | 1998-10-30 | 2003-05-13 | University Of Southern California | Use of immunopotentiating sequences for inducing immune response |
AU5178800A (en) * | 1999-06-01 | 2000-12-18 | Cornell Research Foundation Inc. | Activation of dendritic cells to enhance immunity |
US7361329B2 (en) * | 2000-04-21 | 2008-04-22 | Chemocentryx, Inc. | Compositions for inducing an immune response |
WO2002103024A2 (en) | 2001-06-14 | 2002-12-27 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
SE0102327D0 (sv) | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
WO2003035106A1 (en) * | 2001-10-24 | 2003-05-01 | Chemocentryx | Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen |
WO2004044155A2 (en) * | 2002-11-07 | 2004-05-27 | Beth Israel Deaconess Medical Center | MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
JP4571586B2 (ja) | 2003-09-05 | 2010-10-27 | 一般財団法人化学及血清療法研究所 | プロテアーゼ耐性seb改変体およびそれを含むワクチン |
BR112014018035A8 (pt) * | 2012-02-08 | 2017-07-11 | Premune Ab | Prevenção de doenças inflamatórias em mamíferos domésticos exceto humanos |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145676A (en) * | 1981-09-08 | 1992-09-08 | The Rockefeller University | Method and agents for promoting wound healing |
US4994369A (en) * | 1987-12-15 | 1991-02-19 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | T-cell activation related gene |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
JP2756368B2 (ja) * | 1989-09-19 | 1998-05-25 | エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム | 組換えポリペプチド及びペプチド、それをコードする核酸並びに結核の診断におけるこれらのポリペプチド及びペプチドの使用 |
SE8903100D0 (sv) * | 1989-09-20 | 1989-09-20 | Pharmacia Ab | New pharmaceutical agent |
CA2078003C (en) * | 1990-01-17 | 2006-11-21 | David S. Terman | Tumor killing effects of enterotoxins and related compounds |
WO1993024136A1 (en) * | 1991-01-17 | 1993-12-09 | Terman David S | Tumor killing effects of enterotoxins, superantigens, and related compounds |
EP0499003A1 (en) * | 1991-02-14 | 1992-08-19 | N.V. Innogenetics S.A. | Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
WO1994004196A1 (en) * | 1992-08-14 | 1994-03-03 | Imperial Cancer Research Technology Limited | Tumour therapy |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
AU7177494A (en) * | 1993-06-25 | 1995-01-17 | Board Of Regents, The University Of Texas System | Pore-forming and superantigen encoding toxin cassettes for gene therapy |
-
1995
- 1995-12-29 US US08/580,806 patent/US5935568A/en not_active Expired - Fee Related
-
1996
- 1996-05-20 EP EP96914743A patent/EP0850071A4/en not_active Withdrawn
- 1996-05-20 CA CA002221305A patent/CA2221305A1/en not_active Abandoned
- 1996-05-20 KR KR1019970708220A patent/KR19990014875A/ko not_active Application Discontinuation
- 1996-05-20 JP JP8535139A patent/JPH11508762A/ja not_active Ceased
- 1996-05-20 AU AU58016/96A patent/AU704012B2/en not_active Ceased
- 1996-05-20 WO PCT/US1996/007432 patent/WO1996036366A1/en not_active Application Discontinuation
-
1997
- 1997-11-17 MX MX9708854A patent/MX9708854A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU5801696A (en) | 1996-11-29 |
EP0850071A1 (en) | 1998-07-01 |
EP0850071A4 (en) | 2005-05-25 |
JPH11508762A (ja) | 1999-08-03 |
AU704012B2 (en) | 1999-04-01 |
WO1996036366A1 (en) | 1996-11-21 |
KR19990014875A (ko) | 1999-02-25 |
US5935568A (en) | 1999-08-10 |
CA2221305A1 (en) | 1996-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9708854A (es) | Terapia de genes para regulacion de celulas efectoras. | |
CY1119951T1 (el) | Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv | |
CA2223433A1 (en) | Ob protein compositions and methods | |
IL160015A0 (en) | Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases | |
DE69731540D1 (de) | Behandlung von diarrhoe | |
ATE323169T1 (de) | Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren | |
DE69635899D1 (de) | Polypeptid, das die differenzierung unterdrueckt | |
WO1999046366A8 (en) | Uses for humane non-autologous mesenchymal stem cells | |
NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
HUP9800028A2 (hu) | Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének | |
EP0702563A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND HYPERPROLIFERATIVE DISEASES | |
NO960309L (no) | Agonister og antagonister for humaninterleukin-10 | |
NO931141L (no) | Tnf-muteiner | |
MX244498B (es) | Recombinacion especifica de la secuencia de adn en celulas eucarioticas. | |
EA200700656A1 (ru) | Стабильные жидкие композиции плазмидной днк | |
Schluesener et al. | Transient in vivo activation of rat brain macrophages/microglial cells and astrocytes by immunostimulatory multiple CpG oligonucleotides | |
DE69635349D1 (de) | Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung | |
WO1994006449A3 (en) | Morphogen-induced liver regeneration | |
DE69833876D1 (de) | Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren | |
NZ504445A (en) | Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive | |
IL123642A (en) | Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration | |
WO2000045849A3 (en) | Use of cationic lipids to generate anti-tumor immunity | |
AU6987696A (en) | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells | |
BR0317132A (pt) | Métodos de diagnóstico e tratamento de doença pulmonar intersticial | |
WO2001024764A3 (en) | Cell targeting compositions and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |